COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Fulcrum Therapeutics to Present at Upcoming Investor Meetings26/08/2025
-   
  Proxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue Discovery26/08/2025
-   
  Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer26/08/2025
-   
  Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)26/08/2025
-   
  PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)26/08/2025
-   
  Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference26/08/2025
-   
  Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony26/08/2025
-   
  Cogent Biosciences Announces Participation in the Citi Biopharma Conference26/08/2025
-   
  Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements26/08/2025
-   
  Prime Medicine to Participate in Upcoming Investor Conferences26/08/2025
-   
  InnovAge to Announce Fourth Quarter and Fiscal 2025 Financial Results and Host Conference Call Tuesday, September 9, 202526/08/2025
-   
  Vor Bio to Participate in Upcoming Investor Conferences26/08/2025
-   
  Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform26/08/2025
-   
  BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal26/08/2025
-   
  Altimmune to Participate in Upcoming Investor Conferences26/08/2025
-   
  Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine26/08/2025
-   
  Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology26/08/2025
-   
  Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering26/08/2025
-   
  Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria26/08/2025
Pages